Treatment of UV-causing skin pre-cancer lesions FDA approves innovative alternative therapies

Klisyri (tirbanibulin) is a micro-tube inhibitor that, by inhibiting micro-tube polymerization, can promote apoptosis of the growth cells and is suitable for local treatment of photochemic keraturation of the face or scalp.
and Almirall reached a research and development and promotion partnership in 2017 to develop tirbanibulin in the United States and Europe.
FDA approval is based on data from two randomized double-blind, form-containing, key Phase 3 clinical trials that evaluated the efficacy and safety of Klisyri's 1% ointment in 702 adult patients with facial or scalp photochloric antication.
the number of patients treated with tirbanibulin with a complete removal of facial or scalp lesions increased significantly on the 57th day compared to the deformation agent.
: s1. Athenex Announcs FDA Approval of Klisyri ® (Tirbanibulin) for The Treatment of Actinic Keratosis on Face or Scalp. Retrieved December 15, 2020, from。